UPB
NASDAQUpstream Bio Inc.
Price$6.09-3.25 (-34.80%)
2026-03-112026-06-12
News · 26 weeks44+140%
2025-12-212026-06-14
Mix3290d
- Insider11(34%)
- SEC Filings10(31%)
- Other8(25%)
- Analyst3(9%)
Latest news
25 items- PRUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with chronic rhinosinusitis
- ANALYSTUpstream Bio downgraded by Analyst with a new price targetAnalyst downgraded Upstream Bio from Overweight to Neutral and set a new price target of $8.00
- INSIDERSEC Form 4 filed by Director Beckman Daniella4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Renaud Ronald C Jr4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Fleming Harold Edward4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Ruddy Marcella K.4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Chimovits Erez4 - Upstream Bio, Inc. (0002022626) (Issuer)
- SECUpstream Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026. The presentation will feature a responder analysis examining the proportion of patients who achieved clinically meaningful improvements in key measures of disease with verek
- ANALYSTH.C. Wainwright initiated coverage on Upstream Bio with a new price targetH.C. Wainwright initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $36.00
- PRUpstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceWALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET. A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio's website on the day of the event. A replay will be available on the Company's website following the presentation. About Upstream BioUpstream
- PRUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers – WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new data from the Phase 2 VIBRANT trial evaluatin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)
- SECSEC Form 10-Q filed by Upstream Bio Inc.10-Q - Upstream Bio, Inc. (0002022626) (Filer)
- SECUpstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in COPD ongoing; Company to cap further enrollment; data now expected in the second half of 2027 – – Upcoming data presentations at ATS and EAACI to further elaborate the clinical profile of verekitug – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato
- PRUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in
- SECSEC Form DEFA14A filed by Upstream Bio Inc.DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form DEF 14A filed by Upstream Bio Inc.DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)
- ANALYSTUpstream Bio downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Upstream Bio from Outperform to In-line and set a new price target of $15.00
- SECSEC Form 8-K filed by Upstream Bio Inc.8-K - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form 424B5 filed by Upstream Bio Inc.424B5 - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form S-8 filed by Upstream Bio Inc.S-8 - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form 10-K filed by Upstream Bio Inc.10-K - Upstream Bio, Inc. (0002022626) (Filer)
UPB FAQ
6 questionsWhere does UPB stock trade?
Upstream Bio Inc. (UPB) is listed on NASDAQ.What sector and industry is UPB in?
Upstream Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Upstream Bio Inc. go public?
Upstream Bio Inc. (UPB) completed its IPO in 2024.What are analysts saying about UPB?
Upstream Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $800.00 price target on 2026-06-12.What companies are similar to UPB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare UPB side-by-side with any of them on Quantisnow.How can I track UPB on Quantisnow?
Quantisnow aggregates Upstream Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UPB to receive live email and push alerts on every new disclosure.